Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | CD38 | P28907 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10320309 | 0.88 | PPARG (0.57) | NPC1LMNAMEN1KMT2APPARG | |
| Hydrochloric Acid SCHEMBL10324856 | 0.86 | PPARG (0.56) | NPC1LMNAMEN1KMT2APPARG | |
| SCHEMBL10322933 | 0.86 | HDAC8 (0.56) | MEN1KMT2APPARGHPGDALDH1A1 | |
| SCHEMBL10320558 | 0.86 | ALDH1A1 (0.67) | LMNAPPARGHPGDALDH1A1CA2 | |
| SCHEMBL10318179 | 0.85 | NPC1 (0.55) | NPC1LMNAMEN1HCRTR1KMT2A | |
| SCHEMBL15276210 | 0.82 | APEX1 (0.58) | NPC1LMNAMEN1HCRTR1KMT2A | |
| SCHEMBL13947495 | 0.80 | NPC1 (0.61) | NPC1MEN1HCRTR1KMT2AAPEX1 | |
| SCHEMBL30462959 | 0.80 | NPC1 (0.61) | NPC1MEN1HCRTR1KMT2AAPEX1 | |
| SCHEMBL5332860 | 0.80 | NPC1 (0.72) | NPC1MEN1KMT2AHPGDAPEX1 | |
| SCHEMBL10321484 | 0.79 | TP53 (0.59) | LMNAKMT2APPARGALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012098066-A1 | 1,6- AND 1,8-NAPHTHYRIDINES USEFUL AS DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | claimed |
| WO-2012098070-A1 | QUINOLINE DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | claimed |
| WO-2012098065-A1 | PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | claimed |
| US-20120184548-A1 | CARBOXYLIC ACID ARYL AMIDES | DOMINIQUE ROMYR (US) | 2012-07-19 | — | — | US | claimed |
| US-20120184542-A1 | PYRIDO PYRIMIDINES | ANDERSON KEVIN (US) | 2012-07-19 | — | — | US | claimed |
| US-20120184562-A1 | 1,6- AND 1,8-NAPHTHYRIDINES | LUK KIN-CHUN (US) | 2012-07-19 | — | — | US | claimed |
| WO-2012098066-A1 | 1,6- AND 1,8-NAPHTHYRIDINES USEFUL AS DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012098065-A1 | PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012098070-A1 | QUINOLINE DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| US-20120184548-A1 | CARBOXYLIC ACID ARYL AMIDES | DOMINIQUE ROMYR (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184562-A1 | 1,6- AND 1,8-NAPHTHYRIDINES | LUK KIN-CHUN (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184542-A1 | PYRIDO PYRIMIDINES | ANDERSON KEVIN (US) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184548-A1 | CARBOXYLIC ACID ARYL AMIDES | GOT1, PPARG, PPARA | NPC1 344/4885LMNA 4174/4885MEN1 2323/4885 |
| US-20120184542-A1 | PYRIDO PYRIMIDINES | TYMS, TYMP, DPYD | NPC1 1780/4885LMNA 1119/4885MEN1 1193/4885 |
| US-20120184562-A1 | 1,6- AND 1,8-NAPHTHYRIDINES | PSEN1, BRCA1, PSEN2 | NPC1 29/4885LMNA 182/4885MEN1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.